Antigen-binding affinity is a key determinant of the durable antitumor activity of CD5 CAR-T cells

Jeong-Hoon Jeong1, Yu Ri Seo1, Seung Rok Yu1

  • 1Curocell Inc., Daejeon 34002, Republic of Korea.

PubMed

Insights

Modulating antigen-binding affinity in chimeric antigen receptor (CAR)-T cell therapy reduces T cell fratricide and exhaustion. Low-affinity CD5 CAR-T cells show promise for improved antitumor activity and simplified manufacturing.

Area of Science:

  • Immunotherapy
  • Cellular Therapy
  • Oncology

Background:

  • T cell fratricide is a major limitation in chimeric antigen receptor (CAR)-T cell therapies, hindering optimal antitumor efficacy.
  • Existing strategies to overcome T cell fratricide often involve complex gene editing techniques.

Purpose of the Study:

  • To investigate antigen-binding affinity modulation as a strategy to mitigate T cell fratricide.
  • To develop and evaluate low-affinity CD5-specific CAR-T cells for reduced fratricide and T cell exhaustion.

Main Methods:

  • Engineering CD5-specific CAR-T cells with varying antigen-binding affinities using monoclonal antibodies.
  • Comparing the fratricide and T cell exhaustion levels of low-affinity CAR-T cells against high-affinity counterparts.

Main Results:

  • Low-affinity CD5 CAR-T cells demonstrated significantly reduced T cell fratricide compared to high-affinity versions.
  • Diminished T cell exhaustion was observed in the low-affinity CAR-T cell infusion product.
  • These outcomes suggest a correlation with improved long-term antitumor responses.

Conclusions:

  • Antigen-binding affinity modulation is an effective strategy to mitigate T cell fratricide in CAR-T cell therapy.
  • This approach offers a simpler alternative to gene editing for CAR-T cell manufacturing.
  • Optimizing affinity may enhance therapeutic outcomes and simplify the production of CD5 CAR-T cells.